

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/200557 A1

(51) International Patent Classification:

A61K 31/5355 (2006.01) A61K 9/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)
A61K 45/06 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/EP2022/057895

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,295 26 March 2021 (26.03.2021) US
63/208,728 09 June 2021 (09.06.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **SMITH, Simon Andrew**; ASTRAZENECA
UK LIMITED, 1 Francis Crick Avenue, Cambridge Bio-
medical Campus, Cambridge Cambridgeshire CB2 0AA
(GB). **DEAN, Emma Jane**; ASTRAZENECA UK LIMIT-
ED, 1 Francis Crick Avenue, Cambridge Biomedical Cam-

pus, Cambridge Cambridgeshire CB2 0AA (GB). **LEE, Jeeyun**; Division of Hematology-Oncology, Department of Medicine, Building A-5, Samsung Medical Centre Sungkyunkwan University, School of Medicine, Irwon-ro 115, Gangnamgu, Seoul 135-710 (KR).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Milstein Building, Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: COMBINATION TREATMENTS FOR MELANOMA

Figure 1



(57) Abstract: Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a patient who has previously received immunotherapy.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*